Tag
Ravulizumab, a terminal complement C5 inhibitor, significantly reduces proteinuria in adults with IgA nephropathy, demonstrating safety and biomarker improvements in phase 2 and 3 trials, highlighting its therapeutic potential.
Avacincaptad pegol significantly reduces progression of ellipsoid zone degradation and geographic atrophy lesion growth, highlighting its potential to preserve photoreceptor integrity in AMD patients.
In a phase 2 randomized trial, oral vemircopan did not improve clinical outcomes over placebo in AChR-antibody–positive generalized myasthenia gravis, despite a mechanistically attractive strategy to selectively inhibit the alternative comp
In the phase 3 VALIANT trial, pegcetacoplan, a C3/C3b inhibitor, produced a large, rapid reduction in proteinuria versus placebo at 26 weeks in patients with C3 glomerulopathy or primary immune‑complex MPGN, with an acceptable short-term sa
The APPEAR-C3G phase 3 trial demonstrates that oral iptacopan significantly reduces proteinuria and is well tolerated in adults with C3 glomerulopathy, an ultra-rare glomerulonephritis linked to alternative complement pathway overactivation
